Literature DB >> 11325491

Localised spontaneous regression in mesothelioma -- possible immunological mechanism.

B W Robinson1, C Robinson, R A Lake.   

Abstract

Malignant mesothelioma (MM) is an aggressive tumor usually associated with asbestos exposure. Although it can remain stable for prolonged periods, it has not been described to spontaneously regress. MM tumors are thought to be immunogenic based both on animal studies and on the good responses in some humans treated with immunotherapy. Here we present a case of pleural MM in which a transient spontaneous regression was associated with tumor tissue infiltration with mononuclear cells and serological evidence of anti-MM reactivity. The patient's tumor eventually progressed and with this progression there was evidence of loss of serological reactivity to some, but not all, of her MM antigens. The patient survived for 20 months and, in contrast to her initial biopsy, no significant lymphoid infiltrate was detected in her MM tissue at post mortem examination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325491     DOI: 10.1016/s0169-5002(00)00217-8

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

Review 1.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

2.  Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.

Authors:  Paul G Werthmann; Gerhard Saltzwedel; Gunver S Kienle
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 3.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

Review 4.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

5.  A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.

Authors:  Jason F Lester; Angela C Casbard; Saly Al-Taei; Richard Harrop; Lajos Katona; Richard L Attanoos; Zsuzsanna Tabi; Gareth O Griffiths
Journal:  Oncoimmunology       Date:  2018-09-07       Impact factor: 8.110

Review 6.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 7.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.

Authors:  Assunta De Rienzo; William G Richards; Beow Y Yeap; Melissa H Coleman; Peter E Sugarbaker; Lucian R Chirieac; Yaoyu E Wang; John Quackenbush; Roderick V Jensen; Raphael Bueno
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

9.  Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.

Authors:  Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Sanne de Jong; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans
Journal:  J Biomed Biotechnol       Date:  2010-05-23

10.  Malignant pleural mesothelioma with long-term tumor disappearance of a local relapse after surgery: a case report.

Authors:  Masahiko Higashiyama; Kazuyuki Oda; Jiro Okami; Jun Maeda; Ken Kodama; Fumio Imamura
Journal:  J Med Case Rep       Date:  2009-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.